HC Wainwright Forecasts Strong Price Appreciation for Microbot Medical (NASDAQ:MBOT) Stock

Microbot Medical (NASDAQ:MBOT) had its target price lifted by stock analysts at HC Wainwright from $7.00 to $9.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 343.35% from the stock’s current price.

Microbot Medical Price Performance

Shares of MBOT stock opened at $2.03 on Friday. The stock has a 50-day moving average of $1.31 and a 200-day moving average of $1.09. Microbot Medical has a one year low of $0.82 and a one year high of $3.38. The stock has a market cap of $41.09 million, a PE ratio of -2.54 and a beta of 1.46.

Microbot Medical Company Profile

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.